Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 831-847 , October 2008

Bisphosphonates: how do they work?

References 

  1. Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In:  Peck WA editors. Bone and mineral research annual 1. Amsterdam: Excerpta Medica; 1982;p. 319–357
  2. Blomen LJMJ. History of the bisphosphonates: discovery and history of the non medical uses of bisphosphonates. In:  Bijvoet OLM,  Fleisch HA,  Canfield RE,  Russell RGG editor. Bisphosphonates on bones. Amsterdam: Elsevier; 1995;p. 111–124
  3. Benedict JJ. The physical chemistry of the diphosphonates-Its relationship to their structural activity. In:  Donath A,  Courvoisier B editor. Symposium CEMO IV. Nyon Switzerland. Geneva: Editions Medecine est Hygiene; 1982;p. 1–19
  4. van Beek E, Hoekstra M, van de Ruit M, et al. Structural requirements for bisphosphonates actions in vitro. Journal of Bone and Mineral Research. 1994;12:1875–1882
  5. van Beek ER, Lowik CWGM, Ebetino FH, et al. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone. 1998;23:437–442
  6. Leu C-T, Luegmayr E, Freedman LP, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone. 2006;38:628–636
  7. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617–627
  8. Henneman ZJ, Nancollas GH, Ebetino FH, et al. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. Journal of Biomedical Materials Research. Part A. 2008;85:993–1000
  9. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International. 2008;19:733–759
  10. van Beek , Lowik C, Que I, et al. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. Journal of Bone and Mineral Research. 1996;11:1492–1497
  11. Brown RJ, van Beek E, Watts DJ, et al. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of the Dictyostelium discoideum. Journal of Bone and Mineral Research. 1998;13:253–258
  12. Shinoda H, Adamek G, Felix R, et al. Structure-activity relationships of various bisphosphonates. Calcified Tissue International. 1983;35:87–99
  13. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design. 2003;11:196–214
  14. Reszka AA, Rodan GA. Nitrogen-containig bisphosphonate mechanism of action. Mini Reviews in Medicinal Chemistry. 2004;4:711–719
  15. Thompson K, Rogers MJ, Coxon FP, et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis. Molecular Pharmacology. 2006;69(69):1624–1632
  16. Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonates by osteoclasts and non-resorbing cells. Bone. 2008;42:848–860
  17. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcified Tissue International. 2004;75:451–461
  18. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Current Opinion in Pharmacology. 2006;6:307–312
  19. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of pharnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. The Journal of Pharmacology and Experimental Therapeutics. 2001;296:235–242
  20. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. British Journal of Pharmacology. 2006;147:437–445
  21. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The Journal of Clinical Investigation. 1999;104:1363–1374
  22. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006;39:443–452
  23. Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. The Journal of Biological Chemistry. 2005;280:7317–7325
  24. Follet H, Li J, Phipps RJ, et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone. 2007;40:1172–1177
  25. Plotkin LI, Goellner J, Vyas K, et al. A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo. Journal of Bone and Mineral Research. 2007;22(Suppl. 1):S4
  26. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. The Journal of Clinical Investigation. 1997;100:1475–1480
  27. Bravenboer N, Papapoulos SE, Holzman P, et al. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporosis International. 1999;9:489–493
  28. Eriksen EF, Melsen F, Sod E, et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620–625
  29. Recker RR, Weinstein RS, Chesnut CH, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with post-menopausal osteoporosis: results from the BONE study. Osteoporosis International. 2004;15:231–237
  30. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Current Medical Research and Opinion. 2005;21:185–194
  31. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. Journal of Bone and Mineral Research. 2008;23:6–16
  32. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001;29:185–191
  33. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687–694
  34. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone. 2005;37:1–9
  35. Borah B, Dufresne TE, Ritman EL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39:345–352
  36. Roschger P, Mair G, Fratzl-Zelman N, et al. Mineralization status of bone matrix in postmenopausal women during a 10-year alendronate treatment period. Journal of Bone and Mineral Research. 2007;22(Suppl. 1):S129
  37. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research. 2000;15:613–620
  38. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–531
  39. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves trabecular bone microarchitecture in dog vertebra. Journal of Bone and Mineral Research. 2003;18:512–520
  40. Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39:872–879
  41. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. Journal of Bone and Mineral Research. 2007;22:1502–1509
  42. Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;41:378–385
  43. Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clinical Pharmacokinetics. 2005;44:551–570
  44. Cremers SCLM, Papapoulos SE, Gelderblom H, et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. Journal of Bone and Mineral Research. 2005;20:1543–1547
  45. Christiansen C, Phipps R, Burgio D, et al. Comparison of risedronate and alendronate pharmacokinetics at clinical doses. Osteoporosis International. 2003;14(Suppl. 7):S38
  46. Rosen CJ, Hochberg M, Bonnick S, et al. Treatment with once-weekly alendronate compared to once-weekly risedronate in women with postmenopausal osteoporosis: a randomized, double-blind study. Journal of Bone and Mineral Research. 2005;20:141–151
  47. Papapoulos SE, Cremers SCLM. Prolonged bisphosphonate release after treatment in children. The New England Journal of Medicine. 2007;356:1075–1076
  48. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 1997;12:1700–1707
  49. Cremers S, Sparidans R, den Hartigh J, et al. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. European Journal of Clinical Pharmacology. 2002;57:883–890
  50. Bone HG, Hosking D, Devogalaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New England Journal of Medicine. 2004;350:1189–1199
  51. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1586–1592
  52. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Journal of Bone and Mineral Research. 2004;19:1250–1258
  53. Eastell R, Barton I, Hannon RA. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research. 2003;18:1051–1056
  54. Balena R, Toolan BC, Shea M, et al. The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in overiectomized nonhuman primates. The Journal of Clinical Investigation. 1993;92:2577–2586
  55. Lalla S, Hothorn LA, Hag N, et al. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis International. 1998;8:97–103
  56. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatments with antiresorptive drugs. The American Journal of Medicine. 2002;112:281–289
  57. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. The Journal of Clinical Endocrinology and Metabolism. 2000;85:231–236
  58. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis and Rheumatism. 1999;42:1246–1254
  59. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate end point. Statistics in Medicine. 2001;20:3175–3188
  60. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drags: some issues with meta-analysis. Journal of Bone and Mineral Research. 2004;19:330–337
  61. Papapoulos SE. Determinants of bone strength and clinical practice; effects of bisphosphonates. Bone. 2007;41:S3–S7
  62. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541
  63. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA : The Journal of the American Medical Association. 1998;280:2077–2082
  64. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. The New England Journal of Medicine. 1995;333:1437–1443
  65. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis International. 1999;9:461–468Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA : The Journal of the American Medical Association. 1999;282:1344–1352
  66. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. The New England Journal of Medicine. 2001;344:333–340
  67. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporosis International. 2000;11:83–91
  68. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 2004;19:1241–1249
  69. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 2007;356:1809–1822
  70. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. The New England Journal of Medicine. 2007;357:nihpa40967
  71. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. Journal of Bone and Mineral Research. 2002;17:1057–1064
  72. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. Journal of Bone and Mineral Research. 2004;19:728–736
  73. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. Journal of Bone and Mineral Research. 2007;22:135–141
  74. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA : The Journal of the American Medical Association. 1997;277:1159–1164
  75. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews. 2002;23:508–516
  76. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews. 2002;23:517–523
  77. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis International. 2005;16:468–474
  78. Adachi JD, Rizzoli R, Boonen S, et al. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clinical and Experimental Research. 2005;17:150–156
  79. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International. 2005;16:1291–1298
  80. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008;(1):CD001155
  81. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008;(1):CD004523
  82. Nguyen ND, Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. Journal of Bone and Mineral Research. 2006;21:340–349
  83. Cranney A, Wells G, Yetisir L, et al. Ibandronate for the prevention of non-vertebral fractures: A pooled analysis of individual patient data. Osteoporosis International,. 29 July 2008;[Epub ahead of print]
  84. Gasser JA, Ingold P, Green J. A single IV injection of equipotent doses of alendronate, risedronate, ibandronate and zoledronic acid exerts a bone protective effect of similar magnitude and duration in ovariectomized rats. Journal of Bone and Mineral Research. 2004;19(Suppl. 1):S307
  85. Papapoulos SE, Schimmer RC. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Annals of the Rheumatic Diseases. 2007;66:853–858
  86. McClung MR, Wasnich RD, Hosking DJ, et al. Early Postmenopausal Intervention Cohort Study. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4879–4885
  87. Wasnich RD, Bagger YZ, Hosking DJ, et al., Early Postmenopausal Intervention Cohort Study Group  Changes in bone mineral density and turnover after alendronate or estrogen withdrawal. Menopause. 2004;11:622–630
  88. Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in post-menopausal Danish women up to 7 years after treatment withdrawal. Bone. 2003;33:301–307
  89. Landman JO, Hamdy NAT, Pauwels EKJ, et al. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3465–3468
  90. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA : The Journal of the American Medical Association. 2006;296:2927–2938
  91. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis International. 2008;19:365–372
  92. Neele SJM, Evertz R, De Valk-De Roo Get, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002;30:599–603
  93. Schwartz AV, Bauer DC, Cauley JA, et al. Efficacy of continued alendronate for fractures in women without vertebral fracture. Journal of Bone and Mineral Research. 2007;22(Suppl. 1):S16–S17
  94. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcified Tissue International. 2004;75:462–468
  95. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. The Journal of Clinical Endocrinology and Metabolism. 2005;90:1294–1301
  96. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. The Journal of Bone and Joint Surgery. British Volume. 2007;89:349–353
  97. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008;39:224–231
  98. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. The New England Journal of Medicine. 2008;358:1304–1305
  99. Obermaier-Pietsch CB, Marin F, McCloskey E, et al. Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: results from the Eurofors trial. Calcified Tissue International. 2007;80(Suppl. 1):s137
  100. Delmas P, Watts N, Miller P, et al. Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. Journal of Bone and Mineral Research. 2007;22(Suppl. 1):S27
  101. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122–128
  102. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2007;22:1479–1491
  103. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841–847

PII: S1521-690X(08)00079-1

doi: 10.1016/j.beem.2008.07.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 831-847 , October 2008

Article Tools

* Image Usage & Resolution